Show simple item record

dc.contributor.authorSalvato, M.S.
dc.contributor.authorMedina-Moreno, S.
dc.contributor.authorZapata, J.C.
dc.contributor.authorHsu, H.
dc.contributor.authorGuzmán-Cardozo, C.
dc.date.accessioned2020-02-18T17:07:49Z
dc.date.available2020-02-18T17:07:49Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079121014&doi=10.3390%2fpathogens8030133&partnerID=40&md5=e87d4de99a5c6634526bb201d00c882f
dc.identifier.urihttp://hdl.handle.net/10713/12031
dc.description.abstractLassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact. Caused by Lassa virus (LASV), the disease is a scourge on populations in endemic areas of West Africa, where reported incidence is higher. Here, we report construction, characterization, and preclinical efficacy of a novel recombinant vaccine candidate GEO-LM01. Constructed in the Modified Vaccinia Ankara (MVA) vector, GEO-LM01 expresses the glycoprotein precursor (GPC) and zinc-binding matrix protein (Z) from the prototype Josiah strain lineage IV. When expressed together, GP and Z form Virus-Like Particles (VLPs) in cell culture. Immunogenicity and efficacy of GEO-LM01 was tested in a mouse challenge model. A single intramuscular dose of GEO-LM01 protected 100% of CBA/J mice challenged with a lethal dose of ML29, a Mopeia/Lassa reassortant virus, delivered directly into the brain. In contrast, all control animals died within one week. The vaccine induced low levels of antibodies but Lassa-specific CD4+ and CD8+ T cell responses. This is the first report showing that a single dose of a replication-deficient MVA vector can confer full protection against a lethal challenge with ML29 virus. Copyright 2019 by the authors.en_US
dc.description.sponsorshipen_US
dc.description.urihttps://doi.org/10.3390/pathogens8030133en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofPathogens
dc.subjectCell-mediated immunityen_US
dc.subjectLassa vaccineen_US
dc.subjectReplication-deficient MVA vectoren_US
dc.subjectSingle-dose efficacyen_US
dc.subjectVLP formationen_US
dc.titleA single dose of modified vaccinia ankara expressing lassa virus-like particles protects mice from lethal intra-cerebral virus challengeen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/pathogens8030133


This item appears in the following Collection(s)

Show simple item record